BioStock: Aqilion aims for best-in-class with new programme

Aqilion is in the business of discovering and developing new drug targets that could reduce the burden of chronic inflammatory illnesses. The company has three ongoing pipeline projects, and a fourth programme has just been announced with PKCtheta as the target. Aqilion’s CEO Sarah Fredriksson joined us in the studio to tell us all about it!

Watch the interview at biostock.se:

Aqilion aims for best-in-class with new programme - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/